Goldman Sachs
ONCT

Goldman Sachs’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Goldman Sachs’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-658
Closed -$12K – 6364
2022
Q3 		$12K Sell
658
-8,824
-93% -$189K ﹤0.01% 6017
2022
Q2 		$211K Buy
9,482
+1,090
+13% +$24.3K ﹤0.01% 5617
2022
Q1 		$233K Buy
8,392
+41
+0.5% +$1.49K ﹤0.01% 5804
2021
Q4 		$379K Buy
8,351
+3,152
+61% +$212K ﹤0.01% 5547
2021
Q3 		$434K Buy
5,199
+4,096
+371% +$339K ﹤0.01% 5278
2021
Q2 		$105K Sell
1,103
-4,302
-80% -$511K ﹤0.01% 5933
2021
Q1 		$899K Buy
+5,405
New +$715K ﹤0.01% 4696
2019
Q3 		– Sell
-670
Closed -$89K – 5437
2019
Q2 		$89K Buy
670
+286
+74% +$44.2K ﹤0.01% 4943
2019
Q1 		$64K Sell
384
-187
-33% -$27.9K ﹤0.01% 4980
2018
Q4 		$62K Buy
571
+401
+236% +$80.2K ﹤0.01% 5072
2018
Q3 		$37K Buy
170
+97
+133% +$233K ﹤0.01% 5340
2018
Q2 		$157K Sell
73
-254
-78% -$644K ﹤0.01% 5080
2018
Q1 		$812K Buy
+327
New +$729K ﹤0.01% 4180
2016
Q4 		– Sell
-33
Closed -$36K – 7143
2016
Q3 		$36K Sell
33
-5
-13% -$4.36K ﹤0.01% 6585
2016
Q2 		$29K Buy
38
+24
+171% +$22.4K ﹤0.01% 6602
2016
Q1 		$10K Sell
14
-4
-22% -$3.47K ﹤0.01% 6900
2015
Q4 		$17K Buy
18
+4
+29% +$5.29K ﹤0.01% 6884
2015
Q3 		$14K Sell
14
-10
-42% -$14.6K ﹤0.01% 7101
2015
Q2 		$49K Hold
24
– – ﹤0.01% 6868
2015
Q1 		$23K Sell
24
-7
-23% -$6.96K ﹤0.01% 6885
2014
Q4 		$32K Sell
31
-32
-51% -$28.6K ﹤0.01% 6917
2014
Q3 		$65K Sell
63
-16
-20% -$23.6K ﹤0.01% 6756
2014
Q2 		$153K Buy
79
+15
+23% +$29.7K ﹤0.01% 6380
2014
Q1 		$136K Buy
64
+3
+5% +$7.47K ﹤0.01% 6280
2013
Q4 		$140K Buy
61
+31
+103% +$70.9K ﹤0.01% 6136
2013
Q3 		$86K Buy
30
+1
+3% +$4.98K ﹤0.01% 6198
2013
Q2 		$264K Buy
+29
New +$223K ﹤0.01% 5404

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's ONCT Position: Q4 2022 in Review

Goldman Sachs sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 658 shares — an estimated $12K sold.

Goldman Sachs first reported a position in ONCT in Q2 2013 and held it in 27 quarters. The position peaked at $899K in Q1 2021. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

  • Goldman Sachs reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 658 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $12K.
  • Goldman Sachs first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Goldman Sachs's Oncternal Therapeutics, Inc. Common Stock position peaked at $899K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.